Umeclidinium in Chronic Obstructive Pulmonary Disease: Latest Evidence and Place in Therapy

Overview

Journal Ther Adv Chronic Dis

Publisher Sage Publications

Date 2017 May 12

PMID 28491268

Citations 10

Authors

Kesavan Suresh Babu

Jaymin Bhagwanji Morjaria

Affiliations

Soon will be listed here.

Abstract

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity, mortality and health care expenditure throughout the world. COPD guidelines recommend the use of long-acting muscarinic antagonist (LAMA) either alone or in combination with a long-acting β agonist (LABA). For over 10 years, tiotropium was the only LAMA that was used in the management of COPD. Over the past few years, various new drugs have been identified that act on the muscarinic receptors and β receptors. Umeclidinium (Umec) is a new LAMA currently approved for use in patients with COPD either as monotherapy or in combination with vilanterol (Vil). Both Umec alone and in combination with Vil delivered through a multi-dose dry powder Ellipta™ device have shown improvement in lung function, health-related quality of life and exacerbation frequency in patients with COPD. This review provides an overview of the pharmacology, pharmacodynamics and pharmacokinetics of Umec, and evaluates the clinical efficacy and safety studies in patients with COPD.

Citing Articles

Cardiovascular Events with the Use of Long-Acting Muscarinic Receptor Antagonists: An Analysis of the FAERS Database 2020-2023.

Matera M, Calzetta L, Rogliani P, Hanania N, Cazzola M Lung. 2024; 202(2):119-125.

PMID: 38321329 PMC: 11009752. DOI: 10.1007/s00408-024-00677-3.

A four-part guide to lung immunology: Invasion, inflammation, immunity, and intervention.

Gopallawa I, Dehinwal R, Bhatia V, Gujar V, Chirmule N Front Immunol. 2023; 14:1119564.

PMID: 37063828 PMC: 10102582. DOI: 10.3389/fimmu.2023.1119564.

The Efficacy and Safety of Revefenacin for the Treatment of Chronic Obstructive Pulmonary Disease: A Systematic Review.

Zhang J, Xie Y, Kwong J, Ge L, He R, Zheng W Front Pharmacol. 2021; 12:667027.

PMID: 34744701 PMC: 8564370. DOI: 10.3389/fphar.2021.667027.

Mechanisms, Pathophysiology and Currently Proposed Treatments of Chronic Obstructive Pulmonary Disease.

de Oliveira Rodrigues S, da Cunha C, Soares G, Silva P, Silva A, Goncalves-de-Albuquerque C Pharmaceuticals (Basel). 2021; 14(10).

PMID: 34681202 PMC: 8539950. DOI: 10.3390/ph14100979.

Efficacy and Safety of Once-Daily Inhaled Umeclidinium in Asian Patients with COPD: Results from a Randomized, Placebo-Controlled Study.

Zhong N, Zheng J, Lee S, Lipson D, Du X, Wu S Int J Chron Obstruct Pulmon Dis. 2020; 15:809-819.

PMID: 32368027 PMC: 7173840. DOI: 10.2147/COPD.S215011.

References

Caulfield M, Birdsall N . International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev. 1998; 50(2):279-90. View

Slack R, Barrett V, Morrison V, Sturton R, Emmons A, Ford A . In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther. 2012; 344(1):218-30. DOI: 10.1124/jpet.112.198481. View

Feldman G, Maltais F, Khindri S, Vahdati-Bolouri M, Church A, Fahy W . A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016; 11:719-30. PMC: 4827908. DOI: 10.2147/COPD.S102494. View

Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G . Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014; 2(6):472-86. DOI: 10.1016/S2213-2600(14)70065-7. View

Eglen R, Hegde S, Watson N . Muscarinic receptor subtypes and smooth muscle function. Pharmacol Rev. 1996; 48(4):531-65. View

Donohue J, Anzueto A, Brooks J, Mehta R, Kalberg C, Crater G . A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. Respir Med. 2012; 106(7):970-9. DOI: 10.1016/j.rmed.2012.03.012. View

Calverley P . COPD: what is the unmet need?. Br J Pharmacol. 2008; 155(4):487-93. PMC: 2579674. DOI: 10.1038/bjp.2008.362. View

Partridge M, Karlsson N, Small I . Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin. 2009; 25(8):2043-8. DOI: 10.1185/03007990903103006. View

Wessler I, Kirkpatrick C . The Non-neuronal cholinergic system: an emerging drug target in the airways. Pulm Pharmacol Ther. 2002; 14(6):423-34. DOI: 10.1006/pupt.2001.0313. View

10.

Tashkin D, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S . A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008; 359(15):1543-54. DOI: 10.1056/NEJMoa0805800. View

11.

Sousa A, Riley J, Church A, Zhu C, Punekar Y, Fahy W . The effect of umeclidinium added to inhaled corticosteroid/long-acting β2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study. NPJ Prim Care Respir Med. 2016; 26:16031. PMC: 4918053. DOI: 10.1038/npjpcrm.2016.31. View

12.

Hu C, Jia J, Dong K, Luo L, Wu K, Mehta R . Pharmacokinetics and tolerability of inhaled umeclidinium and vilanterol alone and in combination in healthy Chinese subjects: a randomized, open-label, crossover trial. PLoS One. 2015; 10(3):e0121264. PMC: 4376748. DOI: 10.1371/journal.pone.0121264. View

13.

Malerba M, Radaeli A, Montuschi P, Morjaria J . Vilanterol trifenatate for the treatment of COPD. Expert Rev Respir Med. 2016; 10(7):719-31. DOI: 10.1080/17476348.2016.1184976. View

14.

Procopiou P, Barrett V, Bevan N, Biggadike K, Box P, Butchers P . Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach. J Med Chem. 2010; 53(11):4522-30. DOI: 10.1021/jm100326d. View

15.

Gosens R, Zaagsma J, Grootte Bromhaar M, Nelemans A, Meurs H . Acetylcholine: a novel regulator of airway smooth muscle remodelling?. Eur J Pharmacol. 2004; 500(1-3):193-201. DOI: 10.1016/j.ejphar.2004.07.025. View

16.

van Koppen C, Blankesteijn W, Klaassen A, Rodrigues de Miranda J, Beld A, van Ginneken C . Autoradiographic visualization of muscarinic receptors in pulmonary nerves and ganglia. Neurosci Lett. 1987; 83(3):237-40. DOI: 10.1016/0304-3940(87)90092-9. View

17.

Villetti G, Pastore F, Bergamaschi M, Bassani F, Bolzoni P, Battipaglia L . Bronchodilator activity of (3R)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino] carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane bromide (CHF5407), a potent, long-acting, and selective muscarinic M3 receptor.... J Pharmacol Exp Ther. 2010; 335(3):622-35. DOI: 10.1124/jpet.110.170035. View

18.

Maleki-Yazdi M, Kaelin T, Richard N, Zvarich M, Church A . Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med. 2014; 108(12):1752-60. DOI: 10.1016/j.rmed.2014.10.002. View

19.

Barnes P . The role of anticholinergics in chronic obstructive pulmonary disease. Am J Med. 2005; 117 Suppl 12A:24S-32S. DOI: 10.1016/j.amjmed.2004.10.018. View

20.

Belmonte K . Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005; 2(4):297-304. DOI: 10.1513/pats.200504-043SR. View